peptides for skin
ghk-cu is the only skin peptide with a fifty-year mechanistic file. everything else on this page is a smaller bet.
ghk-cu was isolated from human plasma by Pickart in 1973 and has the deepest cosmetic peptide file on the market: a 2010 fibroblast genomics paper documenting modulation of 4,192 genes, three decades of collagen and angiogenesis studies, and a fda-cleared cosmetic ingredient status. afamelanotide (scenesse) became the first melanocortin agonist with an fda approval (oct 8 2019, $20,000 per implant, narrow EPP indication). almost everything else in the skin-peptide market is downstream of those two molecules plus a handful of acetyl-octapeptide topicals with sponsor-funded data.
the cosmetic core.
compounds most directly tied to skin structure, extracellular matrix signaling, and post-procedure remodeling.
- ghk-cu (tier S) — copper-binding tripeptide isolated from human plasma by Pickart in 1973. modulates 4,192 fibroblast genes (Pickart, BioMed Res Int 2010).
- ahk-cu (tier A) — alanine-histidine-lysine copper tripeptide. follicle-stimulation focus, narrower file than ghk-cu.
- klow (tier A) — kpv, bpc-157, ghk-cu, and tb-500 blend used in skin and post-procedure contexts.
- glow (tier A) — bpc-157, ghk-cu, and tb-500 blend. klow without kpv.
where marketing gets louder.
evidence or safety profile more conditional than the cosmetic core.
- melanotan-i (tier C) — alpha-msh analog. approved as afamelanotide (scenesse) by fda oct 8 2019 for erythropoietic protoporphyria. ~$20,000 per implant.
- melanotan-ii (tier C) — non-selective melanocortin agonist. pigment, libido, and appetite-suppression effects are documented in the published melanocortin literature. no approved indication anywhere.
- snap-8 (tier D) — acetyl octapeptide-3 (lipotec, early 2000s). snap-25 mimic. 63% wrinkle-depth reduction in a sponsor study.
- glutathione (tier D) — endogenous redox tripeptide. modest oral and topical skin-brightening data.
specific-question reference.
which peptide has the strongest skin-specific evidence?
ghk-cu. fifty years of mechanistic work since Pickart's 1973 plasma isolation, the 2010 fibroblast genomics paper documenting 4,192 modulated genes, and a fda-cleared cosmetic ingredient status. that does not make every copper peptide equivalent and it does not make every route of administration equivalent.
are glow and klow proven as blends?
no. blend-specific clinical evidence is limited. the rationale comes from component mechanisms: ghk-cu for copper and matrix biology, bpc-157 and tb-500 for repair-pathway biology, kpv for inflammation signaling in klow.
what is the melanotan safety issue?
melanocortin activation changes pigment biology. that is the intended cosmetic effect. it also drives case reports of melanoma transformation, dysplastic-nevi changes, and cardiovascular events in off-label tanning users. afamelanotide (scenesse, fda 2019) is the same class with one narrow EPP approval. mt-ii has no approved indication anywhere.
does topical peptide evidence translate to injectable use?
no. topical, intradermal, and systemic exposure are different evidence questions. the route changes both exposure and risk.
what the safety literature reports.
what safety split matters most?
route. topical cosmetic peptides generally sit in a different risk category than systemic or injectable use. the same molecule answered differently at each route. read the evidence route by route.
why is glutathione iv use a safety concern?
philippine fda 2011 advisory cited kidney dysfunction and stevens-johnson syndrome cases tied to iv skin-lightening protocols. that is the clinical signal that separates it from oral or topical use.
why are blend claims hard to evaluate?
because component evidence does not automatically prove the combined formula has the same outcome, dose-response, or safety profile.
claim checks
related comparisons
reptides grades the research record and cites the literature behind every call. research reference only; not medical advice.